CAT rs1001179 Single Nucleotide Polymorphism Identifies an Aggressive Clinical Behavior in Chronic Lymphocytic...

Area of Science:

• Oncology
• Genetics
• Hematology

Background:

• Chronic lymphocytic leukemia (CLL) exhibits significant clinical heterogeneity despite established prognostic markers.
• High catalase (CAT) expression correlates with aggressive CLL, linked to the rs1001179 SNP T allele in the CAT promoter.

Purpose of the Study:

• To investigate the prognostic value of the CAT rs1001179 single nucleotide polymorphism (SNP) in chronic lymphocytic leukemia (CLL).
• To determine if the CAT rs1001179 SNP can refine risk stratification and personalize therapeutic choices for CLL patients.

Main Methods:

• Genotyping of the CAT rs1001179 SNP in two independent cohorts of CLL patients (n=235 exploratory, n=531 validation).
• Time-to-event modeling analysis was performed to assess the time-to-first-treatment (TTFT).
• Statistical analyses were conducted to evaluate the SNP's independence from other prognostic parameters.

Main Results:

• The TT genotype of the CAT rs1001179 SNP was significantly associated with a shorter TTFT in CLL patients.
• This association remained independent of established prognostic factors in CLL.
• The TT genotype identified patients with faster clinical progression, even within low-risk subgroups.

Conclusions:

• The TT genotype of the CAT rs1001179 SNP is a potential prognostic factor for shorter TTFT in CLL.
• This SNP can enhance risk stratification, leading to improved patient management and personalized treatment strategies for CLL.